FDA allows Antigenics to resume trials; Flumist sales fall short of expectation; Immune Response Corp. adds Hybridon's adjuvant to its Remune program; UPMC tests a SARS vaccine in animals; Genentech and PDL near settlement in patent dispute; Lilly toacquire AME for 400 million dollar; Pfizer returns late-stage arthritis antibody; More evidence that HSCs can regenerate muscle; Disappointing results for Avastin; Procrit trials stopped; Year 2003 product highlights; Cancervax looks to acquire Cuban technology.
展开▼
